

Clinical Oversight Review Board (CORB) Criteria for Prescribing/ Criteria-Based Consultation (CBC) Criteria for Coverage

Daridorexant (Quviviq)

Notes:

- Yes
- ^ Adequate trial is defined as 10 days treatment duration
- * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Non-Formulary **daridorexant (Quviviq)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria: Non-Formulary **daridorexant (Quviviq)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by or in consultation with Mental Health Clinician or Sleep Specialist
- Diagnosis of insomnia on Problem List
- Patient has failed an adequate trial^ of 4 generic sleep medications (zolpidem, zaleplon, eszopiclone, benzodiazepine, traZODone, tricyclic antidepressant, mirtazapine or melatonin) unless contraindication, intolerance*, or allergy.
- Patient has failed and adequate trial^ of lemborexant (Dayvigo) unless contraindication, intolerance*, or allergy.

Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously, and criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously:

Non-Formulary **daridorexant (Quviviq)** will be covered on the prescription drug benefit when the following criteria are met:

- Diagnosis of insomnia on Problem List
- Patient has failed and adequate trial^ of lemborexant (Dayvigo) unless contraindication, intolerance*, or allergy.